Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes
PLOS One · 2025
DOI: 10.1371/journal.pone.0336038 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Eiji Nakatani und 15 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Biguanides, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shiauoka Prefecure.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly recommended as first-line treatment for type 2 diabetes mellitus (T2DM), but head-to-head data comparing them with metformin, the canonical biguanide, remain sparse in Japan.
Objective
To compare the long-term effectiveness and cost of initiating treatment with a biguanide versus an SGLT2 inhibitor, excluding the alternative class for 12 months but permitting other antidiabetic drugs, on a composite of major cardio-cerebrovascular events and all-cause death, and a composite of diabetic complications.
Methods
We emulated a new-user cohort trial using the Shizuoka Kokuho Database (2014–2021). Patients initiating treatment with either a biguanide or an SGLT2 inhibitor, while avoiding the alternative class during the first 12 months but allowing other glucose-lowering agents, were included. Follow-up began at treatment initiation; those who received the comparator drug within 12 months were excluded. After 1:1 propensity-score matching on demographic, clinical, laboratory, and lifestyle variables, cause-specific Cox models estimated hazard ratios (HRs). Daily medication costs were compared.
Results
After matching, 1,246 patients (623 per group) were followed for a median of 2.9 years (maximum 7.2 years). Cardio-cerebrovascular composite: 44/623 biguanide users (7.1%) and 35/623 SGLT2 inhibitor users (5.6%) experienced a first event (HR 0.80, 95% CI 0.51–1.24). Diabetic complications: 86/623 (13.8%) vs. 78/623 (12.5%) (HR 0.88, 95% CI 0.70–1.13). Median daily drug cost was 124.7 JPY for biguanides and 184.0 JPY for SGLT2 inhibitors (P < 0.001).
Conclusion
Using a large-scale regional database from Japan, we found that among adults with type 2 diabetes without prior major cardiac or renal disease, first-line treatment with an SGLT2 inhibitor did not reduce risks of cardio-cerebrovascular events, mortality, or complications compared with metformin, and cost about 50% more.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.
- Allied Medical K.K., Tokyo, Japan.
- Department of Biostatistics and Data Science, Graduate School of Medical Science Nagoya City University, Nagoya, Japan.
- Institute of Humanistic Social Medicine, Tokyo, Japan.
- Shizuoka General Hospital, Shizuoka, Japan.
- Department of Academic Services, 4DIN Ltd., Tokyo, Japan.
ORCID-Profile: Eiji Nakatani
Förderung
- Shiauoka Prefecure
Zitieren
APA
Nakatani, E., Ohno, H., Nagahama, T., Tonoike, T., Yui, H., Satoh, T., Matsunaga, T., Funaki, D., Ueki, C., Ohata, E., Miyakoshi, A., Igarashi, A., Tanaka, Y., Kaneda, H., Kumamaru, H., & Sugawara, A. (2025). Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes. PLOS One. https://doi.org/10.1371/journal.pone.0336038
Vancouver
Nakatani E, Ohno H, Nagahama T, Tonoike T, Yui H, Satoh T, et al. Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes. PLOS One. 2025. doi:10.1371/journal.pone.0336038
BibTeX
@article{Nakatani2025,
author = {Nakatani, Eiji and Ohno, Hiromitsu and Nagahama, Takayoshi and Tonoike, Toru and Yui, Hiromichi and Satoh, Tatsunori and Matsunaga, Taku and Funaki, Daito and Ueki, Chikara and Ohata, Emi and Miyakoshi, Akinori and Igarashi, Ataru and Tanaka, Yoshihiro and Kaneda, Hideaki and Kumamaru, Hiraku and Sugawara, Akira},
title = {Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0336038}
}
EUVIMED